CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: Final published version
Serval ID
serval:BIB_B1D318829039
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.
Journal
British journal of cancer
Author(s)
Voelter V., Zouhair A., Vuilleumier H., Matter M., Bouzourene H., Leyvraz S., Bauer J., Coucke P., Stupp R.
ISSN
0007-0920
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
95
Number
6
Pages
710-6
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Abstract
Patients with rectal cancer are at high risk of disease recurrence despite neoadjuvant radiochemotherapy with 5-Fluorouracil (5FU), a regimen that is now widely applied. In order to develop a regimen with increased antitumour activity, we previously established the recommended dose of neoadjuvant CPT-11 (three times weekly 90 mg m(-2)) concomitant to hyperfractionated accelerated radiotherapy (HART) followed by surgery within 1 week. Thirty-three patients (20 men) with a locally advanced adenocarcinoma of the rectum were enrolled in this prospective phase II trial (1 cT2, 29 cT3, 3 cT4 and 21 cN+). Median age was 60 years (range 43-75 years). All patients received all three injections of CPT-11 and all but two patients completed radiotherapy as planned. Surgery with total mesorectal excision (TME) was performed within 1 week (range 2-15 days). The preoperative chemoradiotherapy was overall well tolerated, 24% of the patients experienced grade 3 diarrhoea that was easily manageable. At a median follow-up of 2 years no local recurrence occurred, however, nine patients developed distant metastases. The 2-year disease-free survival was 66% (95% confidence interval 0.48-0.83). Neoadjuvant CPT-11 and HART allow for excellent local control; however, distant relapse remains a concern in this patient population.
Keywords
Adenocarcinoma, Adult, Aged, Antineoplastic Agents, Phytogenic, Camptothecin, Chemotherapy, Adjuvant, Combined Modality Therapy, Disease Progression, Disease-Free Survival, Dose Fractionation, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prospective Studies, Rectal Neoplasms, Recurrence, Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
28/04/2008 8:45
Last modification date
20/08/2019 16:20
Usage data